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ReviewSchizophrenia, Dopamine and the Striatum:
From Biology to SymptomsRobert A. McCutcheon,1,2,3,4 Anissa Abi-Dargham,5 and Oliver D. Howes1,2,3,4,*Highlights
Techniques for characterising the
mesostriatal dopamine system, both
in humans and animal models, have
advanced signiﬁcantly over the past
decade.
In vivo imaging studies in schizophre-
nia patients demonstrate that dopami-
nergic dysfunction in schizophrenia is
greatest in nigrostriatal as opposed to
mesolimbic pathways.
Better understanding of striatal struc-
ture and function has enhanced our
insight into the neurobiological basis
of psychotic symptoms.
The role of other neurotransmitters in
modulating striatal dopamine function
merits further exploration, and modu-
lating these neurotransmitter systems
has potential to offer new therapeutic
strategies.
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oliver.howes@kcl.ac.uk (O.D. Howes).The mesolimbic hypothesis has been a central dogma of schizophrenia for
decades, positing that aberrant functioning of midbrain dopamine projections
to limbic regions causes psychotic symptoms. Recently, however, advances
in neuroimaging techniques have led to the unanticipated ﬁnding that dopa-
minergic dysfunction in schizophrenia is greatest within nigrostriatal path-
ways, implicating the dorsal striatum in the pathophysiology and calling into
question the mesolimbic theory. At the same time our knowledge of striatal
anatomy and function has progressed, suggesting new mechanisms via which
striatal dysfunction may contribute to the symptoms of schizophrenia. This
Review draws together these developments, to explore what they mean for
our understanding of the pathophysiology, clinical manifestations, and treat-
ment of the disorder.
Schizophrenia and the Striatum
Schizophrenia is a syndrome consisting of positive symptoms (such as delusions and halluci-
nations), negative ones (including ﬂattened affect and lack of motivation), and cognitive ones.
Dysregulated dopaminergic modulation of striatal function is fundamental to many models that
seek to explain the mechanisms underlying the symptoms of schizophrenia [1–4]. Furthermore,
all licensed pharmacological treatments of schizophrenia affect the dopamine system, and
while several atypical antipsychotics have been proposed to act via alternative nondopami-
nergic mechanisms, such as the serotonergic system, it is still the case that they all bind to
dopamine receptors, and there is no clear relationship between efﬁcacy and serotonergic
effects [5].
In this paper, we review how advances in neuroscientiﬁc methods have improved our under-
standing of striatal structure and function. We then examine the evidence regarding striatal
dysfunction in schizophrenia, and discuss how recent ﬁndings suggest a re-evaluation of prior
hypotheses may be required. Finally, we ask what these developments mean for our under-
standing of the clinical manifestations and treatment of the disorder.
Striatal Structure and Function
Striatal Connectivity
The striatum is an integral part of the corticobasal ganglia circuitry. Extensive work mapping its
pathways, as summarised below, suggests that it acts as an integrative hub for information
processing in the brain.
Initial primate research aimed at mapping striatal connections involved lesioning cortical areas
and recording the location of subsequent striatal degeneration. Later work used retrograde
tracers injected into the striatum to determine both cortical and midbrain connections [6].
Corticostriatal connections were shown to run in three parallel, and well-segregated pathways,Trends in Neurosciences, March 2019, Vol. 42, No. 3 https://doi.org/10.1016/j.tins.2018.12.004 205
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Glossary
Amphetamine sensitisation:
repetitive administration of
amphetamine leading to
progressively greater amphetamine
induced dopamine release.
Associative striatum:
precommissural dorsal caudate,
postcommissural caudate, and
precommissural dorsal putamen.
Receives afferent connections from
the dorsolateral prefrontal cortex.
Homologous to the rodent
dorsomedial striatum.
Clinical high risk (CHR): individuals
experiencing intermittent or
attenuated psychotic symptoms,
below the level at which a psychotic
disorder would be diagnosed.
Diffusion tensor imaging:
measurement of water diffusion
patterns to infer the white matter
structure of the brain and map
anatomical connectivity between
regions.
Direct pathway: striatal output
pathway, in which D1 MSNs project
directly from the striatum to the
output nuclei of the basal ganglia.
Efference copy: internally generated
replica of an outgoing motor signal,
that signals that the subsequent
motor act is self-generated and
thereby dampens sensory
perceptions occurring as a result of
that act.
Inappropriate affect: emotional
expression not in keeping with the
circumstances that provoked it.
Indirect pathway: striatal output
pathway, in which D2 MSNs project
from the striatum to the output nuclei
of the basal ganglia indirectly via the
pallidum.
Limbic striatum: equivalent to the
ventral striatum. Receives afferent
projections from limbic areas:
ventromedial prefrontal cortext,
orbitofrontal cortex, dorsal anterior
cingulate and medial temporal lobe.
Medium spiny neuron (MSN):
GABAergic projection neurons of the
striatum. Typically classiﬁed as either
D1 type of the direct pathway, and
D2 type of the indirect pathway.
Nucleus accumbens (NAcc): main
component of the ventral striatum.
Passivity phenomenon: symptom
of schizophrenia in which one feels
under external inﬂuence and no
longer in control of one’s movements
or thoughts.that effectively parcellated the striatum into limbic (see Glossary), associative, and sensori-
motor functional subdivisions based on their speciﬁc inputs and outputs (Figure 1A) [7]. At the
time, it was thought that these corticostriatal loops operated in parallel with minimal crosstalk;
an idea referred to as the parallel processing model. Subsequent studies, however, suggested
that in addition to these parallel loops, there are projections from one loop to another [8], which
promote information funnelling from the ventral to dorsal striatum (Figure 1A).
Recent methodological advances have further reﬁned our understanding of corticostriatal
architecture [9,10]. These advances underscore the lack of a strict 1:1 topographic mapping,
and indicate that corticostriatal pathways overlap. Based on its exceptional degree of input
heterogeneity, the associative striatum has been highlighted as an information processing hub
[11]. Furthermore, cluster analysis of corticostriatal input patterns has shown that in addition to
the three subdivisions discussed above, a fourth subdivision is apparent in the tail of the
striatum; its most caudal part [11]. This region receives cortical input from a range of areas
including limbic and auditory cortex, and is distinct in its composition, consisting almost
exclusively of D1 expressing medium spiny neurons (MSNs) [12].
In addition to its widespread cortical connectivity, the striatum has extensive bidirectional con-
nections to the midbrain (Figure 1A). The development of the CLARITY tissue preparation method
(which enables lipid removal, while preserving tissue structure), has allowed for in-depth exami-
nation of mesostriatal connectivity, and has identiﬁed projections from the dorsolateral to dorso-
medial projecting dopamine neurons, suggesting a novel pathway for lateral to medial information
ﬂow, in addition to previously identiﬁed medial to lateral routes (Figure 1A) [13].
Many of these more recent ﬁndings on striatal connectivity have been demonstrated only in
rodents to date, and interspecies differences must be borne in mind when seeking to draw
parallels with primate and human anatomy (Figure 1B) [14]. Human neuroimaging studies have,
however, produced ﬁndings that are in keeping with some of the pathways discussed above.
Resting state functional magnetic resonance imaging (fMRI) [15] and diffusion tensor
imaging [16] studies support the division of the striatum into functional subdivisions. Moreover,
compared to anatomical divisions, these functional subdivisions display greater homogeneity in
terms of dopamine release [16], highlighting their relevance for understanding striatal function.
Likewise, the preclinical ﬁnding that the associative striatum acts as an integrative hub via the
convergence of multiple distal cortical inputs, is consistent with human studies [17–19].
In summary, it appears that, in addition to well-established parallel pathways, there also exists,
across species, a high degree of pathway crossing and information funnelling, with regions in
the associative striatum acting as integrative hubs. Furthermore, there appear to be a variety of
pathways allowing for bidirectional information transfer across the striatum.
Striatal Neurochemistry
Recent advances have reﬁned understanding of striatal neurochemistry. In this section, we
consider these ﬁndings and their implications for mechanisms by which abnormalities of
nondopaminergic neurotransmitter systems may contribute to dopaminergic dysfunction.
We also discuss their relevance for developing new treatment approaches to normalise striatal
dopamine function and possibly treat schizophrenia without requiring dopamine D2/3 receptor
blockade.
Most dopamine neurons have the potential to release GABA as a cotransmitter, and a smaller
proportion corelease glutamate. This cotransmission varies across the striatum, and can206 Trends in Neurosciences, March 2019, Vol. 42, No. 3
Positive psychotic symptoms:
symptoms such as hallucinations,
delusions, and disorganised thought
and behaviour.
Positron emission tomography
(PET): technique in which a
radioactive atom is attached to a
biologically active molecule.
Positrons emitted by this molecule
produce gamma rays that are
detected to allow visualisation of its
anatomical distribution.
Resting state functional magnetic
resonance imaging (fMRI): brain
activity is measured in the absence
of any explicit task, and correlations
between spontaneous ﬂuctuations
allow for the inference of functional
connectivity between regions.
Salience: quality of an item that
causes it to stand out from its
environment.
Sensorimotor striatum:
postcommissural putamen. Receives
afferent projections from motor and
premotor cortical areas. Homologous
to dorsolateral striatum in rodents.
Thought echo: form of auditory
hallucination in which an individual
perceives their thoughts being
spoken aloud as an external
stimulus.moderate the reciprocal relationship between dopaminergic and cholinergic neurons [20].
Speciﬁcally, in the dorsal striatum, dopamine neurons do not corelease glutamate, and the
ﬁring of dopamine neurons in this region is accompanied by pauses in cholinergic interneuron
ﬁring secondary to dopamine D2 receptor and GABA signalling. In the ventral striatum, by
contrast, a burst-pause occurs secondary to glutamate cotransmission [20]. In addition to
these functional differences across the striatum, dopamine receptors themselves show fun-
damentally different responses to dopamine, dependent on their striatal location. D2 receptors
in the accumbens show both greater sensitivity to dopamine and a slower postsynaptic current
compared to those in dorsal regions [21]. This is not secondary to differences in D2/3 ratios, but
rather appears to result from differences in Ga subunits [21].
Corticostriatal neurons synapse upon cholinergic interneurons, which in turn modulate dopa-
mine neurons via nicotinic receptors situated on these dopamine neurons, thereby mediating
the corticostriatal control of striatal dopamine release [22]. It is also these cholinergic inter-
neurons that drive GABA release from dopaminergic neurons [23]. Muscarinic regulation of
striatal dopamine function has also been shown, although there is no evidence that dopamine
neurons in the striatum display muscarinic receptors [24], and it appears this modulation occurs
secondary to a variety of mechanisms, including autoreceptors on cholinergic terminals that
inhibit acetylcholine release [25], endocannabinoid signalling pathways [26], and modulation of
MSN projections to the substantia nigra [27]. In the dorsal striatum both M2 and M4 receptors
are needed for this muscarinic modulation of dopamine release, whereas in the ventral striatum
only M4 receptors are required [24].
Of relevance to the treatment of schizophrenia, Kharkwal et al. demonstrated that the extra-
pyramidal side effects of antipsychotic medications may primarily result from the blockade of
D2 receptors on cholinergic interneurons [28]. Blockade of D2 receptors was shown to
increase the ﬁring of D2 expressing indirect pathway MSNs, both due to the direct effect
on these neurons, and as a result of increased acetylcholine-mediated activation of M1
receptors on the MSNs, occurring as a result of D2 blockade on cholinergic interneurons
(Figure 2A) [28]. The authors suggest that this mechanism may have the potential to minimise
movement side effects, and this is supported by the ﬁnding that the antipsychotic with the
lowest risk of these is clozapine. While the favourable proﬁle of clozapine in this domain may
also result from its low afﬁnity for the D2 receptor and low D2 occupancy at clinically therapeutic
doses, it also displays signiﬁcant antagonism at the M1 receptor, which these ﬁndings suggest
contributes signiﬁcantly to its lack of signiﬁcant movement side effects.
Striatal Function
New ﬁndings regarding striatal anatomy and neurochemistry have also reﬁned our understand-
ing of the functional architecture of the striatum. We now discuss how recent neurobiological
advances relate to our understanding of the role of the striatum in behavioural selection,
salience processing, and habit formation.
The output pathways of the striatum include the direct pathway and indirect pathway, where
D1 expressing MSNs project directly to the output nuclei of the basal ganglia, and D2 type
MSNs project indirectly via the pallidum (Figure 3). Recent ﬁndings suggest, however, that
these pathways are less distinct than previously thought, with D1 and D2 MSNs of the ventral
striatum often not adhering to the direct and indirect pathways, respectively [29,30]. While
these classical pathways better describe the architecture of the dorsal striatum, interpathway
communication has also been demonstrated here. Lateral projections from indirect pathway
MSNs inhibit direct pathway MSNs via GABA release, and striatal dopamine release reducesTrends in Neurosciences, March 2019, Vol. 42, No. 3 207
Co
rt
ex
St
ria
tu
m
M
id
br
ai
n
Dorsomedial SNVentral tegmental area
Dorsolateral PFC Premotor/motor
Amygdala, hippocampus, 
vmPFC, omPFC
Ventrolateral SN
Dorsal
Lateral
Ventral
M
ed
ia
l
PrimateRodent
VTA
SN(
me
dia
l)
SN(
late
ral)
VTA
SN(
dor
som
edi
al)
SN(
ven
tro
late
ral)
Ve
nt
ra
l
st
ria
tu
m
Ve
nt
ra
l
st
ria
tu
m
Do
rs
al
st
ria
tu
m
Ca
ud
ate
Pu
tam
en
NAcc
(A) (B)
Associave
Sensorimotor
Limbic
Figure 1. Striatal Connectivity. (A) Summary of primate tracing studies mapping connections between cortex (top row), striatum (middle), and midbrain (bottom). The
primate striatum can be divided into NAcc, olfactory tubercle, caudate nucleus, and putamen (for simplicity, not indicated in the ﬁgure). The division between caudate
and putamen, however, has little biological relevance [6]. Tract tracing studies showed that striatocortical connections run in three parallel pathways. Motor areas
project to the caudal putamen [117]; dorsolateral prefrontal cortex to caudate and rostral putamen [118]; and limbic areas to the ventral striatum [119]. These
subdivisions were termed the sensorimotor, associative, and limbic striatum. Subsequent research used retrograde tracers injected into striatum to determine midbrain
connections [6,8]. This showed that ventral tegmental area and medial SN project primarily to limbic striatum, while central/ventrolateral parts of the SN project to the
associative and sensorimotor striatum. The striatum in turn has efferents projecting back to the midbrain. In addition to these reciprocal connections, feedforward
striato-nigro-striatal connections allow information to pass along the striatum from limbic to motor regions via the associative striatum [8,112,120]. (B) Summary of
rodent–primate differences in mesostriatal connectivity. In rodents, the ventral striatum is proportionally larger than in primates. The NAcc shell is innervated by the
medial VTA, and the NAcc core by the central VTA, whereas the lateral VTA innervates a region homologous to the associative striatum; the SN also has some
connections to the associative region in addition to the more dorsal regions of the striatum. In primates, the VTA is proportionally smaller; it innervates the ventral
striatum, whereas the dorsal tier SN innervates the associative striatum, and the ventral tier innervates the sensorimotor striatum (for a more detailed review of
differences between primates and rodents see [14,121]). Abbreviations: NAcc, nucleus accumbens; omPFC, orbitomedial PFC; PFC, prefrontal cortex; SN, substantia
nigra; vmPFC, ventromedial PFC; VTA, ventral tegmental area.this GABA release thereby supressing this lateral inhibition [31]. In the opposite direction, direct
pathway neurons show collaterals that bridge across to the indirect pathway [32]. Moreover,
recent ﬁndings indicate that neural activity in both pathways increases when animals initiate
behaviour, in contrast to the classical accelerator/brake model [33,34]. One interpretation of
this ﬁnding is that the activation observed in the indirect pathway corresponds to the suppres-
sion of alternative, undesirable behaviour [35], and that this suppression may occur via
collaterals between direct and indirect pathway MSNs [35] (Figure 2B).
Theactivity ofmesostriataldopamine neuronshas been shown tosignify thediscrepancybetween
expected and actual rewards, which has been termed the reward prediction error [36]. In addition
to reward processing, some models have emphasised the role of mesostriatal dopamine neurons
in assigning salience to environmental stimuli, and their potential relevance to the development of
psychotic symptoms [1]. It has been debated whether mesostriatal dopaminergic neurons carry
information regarding salience that goes beyond reward related information [37,38]. Recent
studies suggest that while dopamine signalling within the ventral striatum is strongly linked to208 Trends in Neurosciences, March 2019, Vol. 42, No. 3
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Figure 2. Striatal Neurochemistry and Neurotransmission. (A) The role of cholinergic interneurons in mediating
extrapyramidal side effects [28]. (i) In wild-type mice, D2Rs mediate inhibitory actions both by directly reducing ﬁring of the
indirect pathway MSN, and by reducing ﬁring of cholinergic interneurons. (ii) In knockout mice without D2Rs on cholinergic
interneurons, D2 antagonism of the MSN by itself is insufﬁcient to induce catalepsy. (iii) Activating, in addition, M1Rs,
results in catalepsy, which occurs due to increased ﬁring of the cholinergic interneuron secondary to D2 antagonism. (B)
The relationship between striatal dopamine, lateral inhibition, and behavioural selection [35]. The ﬁgure illustrates three
scenarios, based on a hypothetical pair of functional units (A and B) each controlling a speciﬁc behavioural outcome
(behaviour A and B, respectively). (i) Localized dopaminergic signalling in functional unit A activates D1 direct pathway
MSNs, while suppressing D2 indirect pathway MSNs, enabling the execution of desired behaviour A. GABAergic lateral
inhibition suppresses competing behaviour coded for by functional unit B. (ii) Spatially disorganised dopaminergic
signalling means that there is nonspeciﬁc activation of multiple functional units, and undesirable behaviours are no longer
suppressed. (iii) Dopamine antagonists enhances the activity of indirect pathway neurons, but without regional speciﬁcity,
meaning that desirable behaviours are also suppressed. Abbreviations: Ach, acetylcholine; DA, dopamine; D2R, dopa-
mine D2 receptor; M1R, M1 muscarinic receptor; MSN, medium spiny neuron.
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stimulus value, dopamine signalling in more dorsal regions does not track value, but rather the
novelty and intensity of stimuli, and in particular threat-related information [13,39,40]. It has also
been recently demonstrated that optogenetic stimulation of dopamine neurons is sufﬁcient to
imbue unremarkable environmental stimuli with motivational properties, and that these stimuli are
subsequently able to evoke dopaminergic activity, despite never having possessed any intrinsic
salience [41]. Recent human positron emission tomography (PET)–fMRI studies also provide
evidence that striatal dopamine has a broader role than simply encoding reward prediction errors,
and is associated with the function of cortical salience networks [42], and making more general
inferences about the state of the environment [43].
Striatal function alonga ventral–dorsal axis is also relevant to habit formation. During the learning of
action–outcome pairings, performance is goal directed and sensitive to changes in outcome
values. After extensive training, however, performance moves to a stimulus–response mode that
is inﬂexible, and no longer responds to changes in outcome. This evolution of behaviour from
contingency-dependent learning to habitual responding has been associated with a shift from
ventral to dorsal striatal processing [44]. Supporting this, lesions to nigrostriatal pathways and
dorsal striatum disrupt habit formation, amphetamine sensitisation encourages habit forma-
tion, and it is the dorsal striatum that is implicated in the habitual responses to drug cues
experienced by addicts [45]. Recent work has focused more speciﬁcally upon the role of the
striatal tail, and is consistent with these earlier ﬁndings in that this region appears to be involved in
storing stable values while the ventral region acts as a ﬂexible coder of information [46].
Striatal Dopamine and Schizophrenia
The Mesolimbic Dogma
Early models of schizophrenia proposed that dysfunction of the mesolimbic pathway underlay
positive psychotic symptoms (Box 1) [4]. Related to that, it was also proposed that newer
antipsychotics beneﬁt from mesolimbic selectivity when compared to older agents [47]. While
questions were raised regarding the precise locus of striatal dysfunction [48], a focus on
mesolimbic pathways persisted, likely due to the absence of robust evidence to refute it. As a
result, the mesolimbic hypothesis became a central dogma of schizophrenia, featured in many
textbooks, and frequently invoked in discussions regarding the pathophysiology of the illness
[1,2,49,50]. As it was not possible to measure limbic dopamine function in vivo, the theory was
based on indirect evidence. Moreover, it originated when the dorsal striatum was thought to be
solely involved in motor function, and unlikely to be involved in psychosis. Subsequent
advances suggest it may in fact be these dorsal regions that play a central role in the
pathophysiology of the disorder.
Postmortem Studies of Striatal Dopamine Function
Early postmortem studies investigating striatal dopaminergic abnormalities produced incon-
sistent results. Initial studies measured concentrations of dopamine, and while some reported
an association between schizophrenia and increased concentrations speciﬁcally in the
nucleus accumbens (NAcc) [51], others found dopamine concentrations elevated speciﬁ-
cally in the dorsal striatum [52]. Moreover, tyrosine hydroxylase activity, the rate-limiting enzyme
in dopamine synthesis, was shown to be elevated throughout the striatum [53], as was
dopamine receptor density [54].
More recently, no differences between patients and controls in terms of either density of
dopaminergic terminals [55], or levels of tyrosine hydroxylase have been found in the NAcc
[56,57]. Inferences from postmortem studies, however, are limited by the fact that most
patients have received antipsychotic drug treatment, which may upregulate dopamine210 Trends in Neurosciences, March 2019, Vol. 42, No. 3
Box 1. Mesolimbic Hypothesis of Schizophrenia
Clinical Findings
The origins of the mesolimbic hypothesis date back to observations that symptoms, displayed during epileptic seizures
localised to limbic areas, were similar to the symptoms of schizophrenia [122]. It was also noted that individuals with
tumours in limbic areas were likely to be diagnosed with schizophrenia [123]. Further support came from research using
electrodes implanted in individuals with schizophrenia, which demonstrated increased activity in limbic regions during
periods of active psychosis [124].
Amphetamine Models
The above-mentioned clinical ﬁndings were not neurotransmitter speciﬁc. The link to dopamine was based on three
complementary ﬁndings. First, that high doses of amphetamines were able to induce a ﬂorid psychotic state [125];
second, that in rodents amphetamine induced dopamine release appeared greatest in the NAcc [126]; and third, that
amphetamine-induced stereotypy was speciﬁc to increased dopaminergic transmission in the NAcc [127].
Antipsychotics
Injections of antipsychotics into the NAcc abolished amphetamine-induced behaviour, but injections into caudate had
no effect [128]. Furthermore, some antipsychotics speciﬁcally upregulated dopamine turnover in the NAcc, supporting
the hypothesis that dopamine blockade of this region was central to the antipsychotic effect of antipsychotics. This was
in keeping with ﬁndings that while typical antipsychotic drugs increased c-fos and neurotensin expression in the NAcc
and dorsal striatum, atypicals affected expression solely in the NAcc, suggesting that the NAcc was central to
antipsychotic effects whereas dorsal actions might be solely related to motor side effects [129].
Together these ﬁndings led to the hypothesis that psychosis is due to overactivity in the mesolimbic dopamine pathway
[2,49,50]. Modern neurochemical imaging ﬁndings, however, suggest that it is within dorsal regions of the striatum that
dopaminergic aberrations are greatest [61] (Figure I).
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receptors [58], and alter presynaptic dopamine function [59], and furthermore dopamine and its
metabolites are greatly affected by death [60].
In vivo Neuroimaging of the Striatum
PET allows quantiﬁcation of the dopamine system in vivo. Radiolabelling of the dopamine
precursor L-dihydroxyphenylalanine enables the measurement of its uptake and conversion in
dopamine neurons to give an index of dopamine synthesis capacity. Alternatively, imaging the
competition between endogenous dopamine and radioligands speciﬁc to postsynaptic dopa-
mine receptors can determine baseline levels of dopamine (following depletion of endogenous
dopamine using compounds such as a-methylparatyrosine), as well as the magnitude of
dopamine release (following a pharmacological or psychological challenge).
Meta-analysis of studies using these PET and single photon emission computed tomography
(SPECT) techniques shows that there is a robust increase in striatal dopamine synthesis and
release in psychosis [61]. There is no evidence of major alterations in dopamine D2/3 receptors,
although it is possible that increased receptor occupancy by raised endogenous dopamine
levels masks this, or alternatively that differences between groups in the afﬁnity state of the
receptor are not detected with the antagonist ligands generally used [62–64].
Early PET and SPECT studies of presynaptic dopamine function could distinguish anatomical
subdivisions of the striatum but lacked sufﬁcient resolution to accurately distinguish between
functional subdivisions. Accordingly, these studies reported outcomes for the whole striatum or
anatomical subdivisions. However, the subsequent development of higher resolution PET
scanners has enabled the assessment of striatal functional subdivisions as well. The ﬁrst
studies to report on these subdivisions in patients with schizophrenia found that the greatest
differences in dopamine function were within the associative striatum, with differences in the
limbic subdivision not reaching statistical signiﬁcance [63,65]. The ﬁnding that dopaminergic
dysfunction is greatest in the associative region has been replicated in multiple studies since
then [63,66–68]. Meta-analysis of these studies found that dopaminergic function was signiﬁ-
cantly elevated in patients relative to controls in associative (Hedges’ g = 0.73) and sensori-
motor regions (g = 0.54), but was not signiﬁcantly altered in the limbic subdivision (Box 1) [61].
Studies investigating presynaptic dopamine function in individuals at clinical high risk (CHR)
of psychosis also found the greatest abnormality to be in the associative striatum [65,69], and
that conversion from CHR to psychosis is associated with a progressive increase in dopamine
synthesis capacity in the dorsal (predominantly sensorimotor) striatum, while no signiﬁcant
change was observed in the limbic subdivision [70].
In a multimodal study, frontal activation during a working memory task was shown to correlate
inversely with associative striatum dopamine synthesis capacity in a CHR group [71]. In the
same sample, dopamine synthesis capacity in the associative striatum correlated with greater
activation in the left inferior frontal region during a verbal ﬂuency task in the CHR group, but not
in the control group [72]. In both studies, no correlations were seen for limbic or sensorimotor
subdivisions. fMRI only studies have shown hypoconnectivity between cortex and dorsal
striatum in individuals with schizophrenia [73–76], CHR individuals [77], and individuals at
genetic risk [73]. Greater activity within the dorsal striatum as measured during resting-state
MRI has also been shown to correlate with psychotic symptoms [78], and treatment response
correlates with increased functional connectivity between the associative striatum and pre-
frontal cortex [79]. Meanwhile, diffusion tensor imaging has found reduced anatomical con-
nectivity between the dorsolateral prefrontal cortex and the associative striatum in212 Trends in Neurosciences, March 2019, Vol. 42, No. 3
schizophrenia [80]. It is important to recognise, however, that some fMRI studies have also
shown alterations in ventral striatal function in patients with psychotic disorders relative to
controls [81].
In summary, in contrast to the mesolimbic theory, in vivo neuroimaging studies have provided
evidence that dopaminergic dysfunction in schizophrenia is greatest within dorsal, as opposed
to ventral regions of the striatum.
How Could Striatal Dysfunction Lead to Symptoms of Schizophrenia?
An ongoing question is how the neurobiological abnormalities identiﬁed in patients translate to
the diverse psychopathology with which they present. We now suggest several mechanisms
whereby striatal dysfunction could contribute to the clinical manifestations of the disorder. It is
important to note, however, that many of these proposals are speculative at this stage, and
furthermore, that schizophrenia is a heterogeneous disorder and no single brain region or
neurotransmitter is likely to be able to account for all symptoms in all patients.
Aberrant Salience and Delusional Form
Theoretical models linking biological substrates to phenomenological experience in psychosis
have frequently built upon the ﬁnding that mesostriatal dopamine signalling is involved in
marking the salience of environmental stimuli [1]. Excessive spontaneous dopamine transients
are proposed to lend irrelevant external or internal stimuli signiﬁcance due to the temporal
association of the stimuli with striatal signalling [1,82]. Although interpretations have often
focused upon the mesolimbic pathway, it is apparent that nigrostriatal pathways are also
involved in signalling salience [13,39,40,83], and the ﬁnding that dopaminergic activity within
dorsal regions of the striatum is tied to signalling threat-related information [39], may have
relevance to the fact that delusions are frequently persecutory in nature.
Existing models have proposed that delusions then develop secondary to cognitive processes
attempting to construct a coherent explanation for these unusual experiences. Historically,
however, discussions regarding the phenomenology of delusions have emphasised form of
thought over content. Delusional form is characterised by a certainty of conviction, that is
accompanied by an inability to shift perspective, and an imperviousness to counterargument
[84]. Given the role of the dorsal striatum in habit formation and the coding of stable values
[44,46], one can speculate that the dopaminergic dysfunction of the dorsal striatum that
accompanies the onset of psychosis could lead to a more habit-oriented mode of cognition,
contributing to the rigid form of thought as well as its unusual content [70].
Another ﬁnding of relevance to theories of aberrant salience attribution in schizophrenia is the
following one. A stimulus, even if initially lacking inherent salience, once paired with dopami-
nergic activity, maintains the ability to evoke dopaminergic activity over time [41]. This suggests
that in psychosis, once an environmental stimulus has been highlighted by aberrant dopamine
signalling, it may maintain its ability to trigger dopaminergic activity, potentially cementing its
position in a delusional framework, even if the system subsequently returns to normal function.
The Dorsal Striatum as an Integrative Hub
The striatum, and speciﬁcally areas of the associative striatum, can be viewed as an integrative
hub. Regions of the caudate receive inputs from nearly the entire cortex [11,17]; and, addi-
tionally, via various connections with the midbrain [13], the associative striatum acts as a
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Given that the striatum performs an integrative role, functional disruption secondary to aberrant
dopamine signalling may lead to the associative impairments observed in schizophrenia. Based
on preclinical models, it has been proposed that the underlying pathophysiology in schizo-
phrenia represents a combination of increased aberrant spontaneous phasic dopamine
release, and a reduction in adaptive phasic release in response to relevant stimuli [82]. This
would lead to increased noise in dopamine signalling in the associative striatum, which could
explain ﬁndings of reduced functional connectivity between the associative striatum and cortex
[73], and could disrupt integration of cortical inputs from emotional, cognitive, and motor areas.
This provides a potential neurobiological correlate for Bleuler’s original description of the
syndrome as principally resulting from a loss of association between thought processes,
emotion, and behaviour [85], and could underlie symptoms such as inappropriate affect.
However, this has yet to be deﬁnitively tested.
Regionally targeted dopamine signalling enables the precise selection of speciﬁc behaviours
over others, and collaterals between direct and indirect pathway MSNs [35] mediate the
appropriate integration of multiple signals (Figure 2B). Undirected dopamine transmission
impairs this mechanism, leading to disorganised behaviour. In contrast, in the context of
pharmacological approaches, D2 antagonism has the ability to supress overactivity within
these systems, but potentially impairs the execution of desired behaviour (Figure 2B).
Abnormal Perceptions and Efference Copies
An efference copy is an internally generated replica of an outgoing motor signal, that has the
effect of dampening sensory perceptions occurring as a result of the motor act, encouraging it
to be perceived as self-authored and avoiding attribution to an external agent. The possibility,
therefore, that disruption of efference copy mechanisms could contribute to passivity phe-
nomena has long been suggested [86].
Efference copies accompanying internally generated motor cortex activity travel via pyramidal
tract neurons to the dorsal striatum [87,88]. There is some evidence that the glutamatergic
corticostriatal neurons thought to encode the efference copy tend to synapse upon the
GABAergic D2 striatal MSNs of the indirect pathway (Figure 3) [87,89,90]. One might
speculate therefore that excessive dopaminergic signalling within the striatum inhibits D2
expressing neurons, thereby reducing activity of the indirect pathway and potentially imped-
ing the appropriate transmission of the efference copy signal, meaning that internally gener-
ated phenomena may not be coded as such. However, this hypothesis remains to be tested,
including in humans, and is only one possible mechanism of disrupted efference copy
signalling.
In addition to motor passivity phenomena, a similar mechanism may contribute to auditory
hallucinations related to inner speech, such as thought echo. Inner speech is in certain
respects a motor act, in that it is thought to result from motor plans for speech that are
subsequently aborted [91]. Recent research suggests that efference copy mechanisms
account for the fact that it is typically easily distinguished from external speech [92]. The
neurobiological correlate of inner speech includes neural activation in cortical areas involved in
the perception of external speech, such as the secondary auditory cortex [93], and these
cortical areas project to the dorsal striatum [18]. Abnormalities of the dorsal striatum have been
associated with auditory hallucinations in studies of brain structure, metabolic rate, and
perfusion, and it is possible that the mechanism discussed above may contribute to the
relationship between these symptoms and striatal dysfunction [94–96].214 Trends in Neurosciences, March 2019, Vol. 42, No. 3
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Figure 3. Mechanisms via Which Excess Striatal Dopamine May Impair Efference Copy Transmission. With
normal striatal dopamine signalling (left), neurons carrying the efference copy signal preferentially synapse onto dopamine-
D2-expressing GABAergic medium spiny neurons of the indirect pathway. Increased dopamine release within the striatum
(right) inhibits these D2-expressing neurons. Excess striatal dopamine may therefore interfere with appropriate transmis-
sion of the efference copy signal. In the auditory areas of the dorsal striatum this could result in inner speech being
mischaracterised as externally generated.Efference-copy mechanisms, however, are less likely to account for auditory hallucinations that
are phenomenologically unrelated to inner speech, and a predictive coding framework, which is
a more generalisable model, seems more relevant in this context. Predictive coding refers to the
idea that the brain compares prior expectations with new sensory evidence, and uses the
discrepancy between the two (the prediction error) to update its model of the world.
The certainty regarding one’s prior expectation is described as the precision of that prediction.
Both the extent of the difference between prior and sensory data, and the precision of these
determine the magnitude of the prediction error [97]. Recent research has demonstrated thatTrends in Neurosciences, March 2019, Vol. 42, No. 3 215
auditory hallucinations are related to a greater ability of priors to inﬂuence perception [98]. It has
also been demonstrated that amphetamine-induced dopamine release in the associative
striatum is associated with this increased weighting of priors [99]. These ﬁndings are com-
plemented by recent preclinical research showing that neurons in the tail of the striatum code
prior beliefs regarding the value of auditory stimuli [100].
Cognitive and Negative Symptoms
It addition to the role that striatal dopamine signalling plays in the development of positive
symptoms, several mechanisms have been suggested for its contribution to the cognitive and
negative symptoms of the disorder as well.
Cognitive impairments in schizophrenia have been suggested to result from cortical hypodo-
maminergia; an idea supported by the importance of cortical dopamine signalling for prefrontal
related cognition [101,102]. Recent work in rodents has extended this framework to include
striatal involvement, by showing that the relationship between cortical and striatal dopamine is
bidirectional, and that increased dorsal striatal dopaminergic signalling can reduce mesocort-
ical dopamine release and produce cognitive deﬁcits [103,104]. While in vivo imaging evidence
for a deﬁcit in cortical dopamine transmission has emerged [105], and the multimodal studies
discussed above have suggested that striatal dysfunction may be functionally linked to cortical
hypofunction, the direction of causality remains unclear and has yet to be determined, including
in human studies [71,72].
Striatal hyperdopaminergia could conceivably result in cognitive impairments either by dis-
rupting signalling between the frontal cortex and associative striatum, or by potentially driving
cortical dopamine dysregulation [103]. Of relevance to this question is an animal model of
striatal D2 receptor overexpression, designed to mimic the increased striatal dopamine
signalling observed in schizophrenia [103,106]. Studies using this model found that striatal
D2 overexpression led to both reductions in cortical dopamine turnover and cognitive deﬁcits
[106]. These abnormalities persisted even following the normalisation of striatal dopamine
transmission, suggesting that while increased striatal dopamine signalling leads to cognitive
impairments, subsequent adaptive changes may underlie their persistence [106]. This could
contribute to the ﬁnding that the attenuation of striatal dopamine transmission with antipsy-
chotics is of limited beneﬁt in treating cognitive symptoms. This potential role of associative
striatum, is also supported by in vivo studies showing that reduced connectivity of the
associative striatum and substantia nigra is related to the severity of cognitive deﬁcits in
schizophrenia [75,107].
There is also evidence that striatal dysfunction may contribute directly to negative symptoms.
Studies using probabilistic learning tasks have shown that negative symptoms in individuals
with schizophrenia may be related to impaired reward-based learning [108–111]. Multiple
studies have demonstrated that the striatum plays a key role in the orchestration of this type of
behaviour [112], and it has been proposed that excessive aberrant dopamine release may
mask adaptive striatal dopamine release, thereby contributing to these behavioural deﬁcits in
schizophrenia [111]. This is consistent with neuroimaging studies showing reduced midbrain
and striatal activation during reward processing in patients [81,113].
Therapeutic Implications
In this section we consider the implications of the evidence discussed earlier for the develop-
ment of new treatments for schizophrenia that are not D2 receptor blockers and that might
address the striatal dopamine dysfunction seen in the disorder.216 Trends in Neurosciences, March 2019, Vol. 42, No. 3
Outstanding Questions
Is anatomically precise modulation of
dopamine signalling within the striatum
possible? The variation across the stri-
atum both in terms of dopamine
receptor distributions, and of the
mechanisms that control striatal dopa-
mine and striatal function, suggests
that it may be, but this remains to be
tested.
Do endocannabinoids, GABAgeric,
cholinergic, and glutamatergic inter-
ventions have therapeutic potential
given their role in modulating striatal
function?
Do primary striatal abnormalities exist
in schizophrenia, or is dysfunction
entirely secondary to upstream pathol-
ogy? Genes associated with schizo-
phrenia, overlap signiﬁcantly with
genes expressed by MSNs but not
with those expressed by dopamine
neurons. Abnormalities such as
patch-matrix differentiation, or ones
associated with cholinergic interneur-
ons might also contribute to striatal
dysfunction in schizophrenia.
Recently, greater densities of afferent
excitatory synapses have been found
in the NAcc of individuals with schizo-
phrenia, this could, via the feedforward
mechanisms discussed (Figure 1A),
drive increased dopamine release in
the dorsal striatum.
Are speciﬁc symptoms associated
with dopamine dysregulation in spe-
ciﬁc striatal loci? For instance, are ver-
bal hallucinations associated with
dopaminergic abnormalities in striatal
regions displaying connectivity to the
secondary auditory cortex? Are motor
symptoms associated with the motor
striatum?
What is the optimal striatal parcella-
tion? Preclinical ﬁndings suggest cur-
rent atlases may oversimplify the
picture, and point at the importance
of improving our understanding of
striatal connectivity. Could we
improve our ability to characteriseAs previously discussed, studies have shown that the magnitude of dopaminergic abnormalities in
schizophrenia variesacross the striatum,with themostmarkeddysfunctionseen in theassociative
striatum. These ﬁndings suggest that anatomically selective modulation of dopamine function is
preferable [61]. This could have the potential beneﬁt of reducing adverse effects that may occur
secondary to dopamine antagonism in regions such as the cortex, where PET imaging evidence
indicates dopamine signalling may be unaltered or even reduced in schizophrenia.
The existing mechanistic understanding of striatal circuitry points at some possible therapeutic
approaches that could allow more anatomically precise modulation of striatal dopamine
function. One such mechanism, as discussed earlier, is muscarinic modulation of striatal
dopamine release. Preclinical studies have shown that M4 positive allosteric modulators
(PAMs) act on striatal MSNs to speciﬁcally inhibit dorsal striatum dopamine release via
endocannabinoid signalling [114,115]. Other preclinical studies have shown that activation
of group 1 metabotropic glutamate receptors may also selectively reduce dorsal striatum
dopamine transmission via interaction with M4 receptors, but that unlike M4 activation, mGlu1
PAMs appear to have the advantage of not reducing motivational responding [115]. Encour-
agingly, a PAM of the M1/M4 receptor has shown efﬁcacy in treating schizophrenia, although
tolerability issues have prevented further clinical trials [116].
Concluding Remarks and Future Perspectives
Recent in vivo imaging evidence consistently suggests that the major abnormality in dopamine
function in schizophrenia is located within the dorsal rather than the limbic striatum. Increasing
knowledge regarding the structure, function, and neurochemistry of the striatum has improved
our understanding of how these dopaminergic abnormalities may lead to symptoms. While
these developments highlight potential pathways for the development of new treatments, the
translation of these advances to meaningful clinical interventions, remains a signiﬁcant chal-
lenge (See Outstanding Questions).
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